✦ LIBER ✦

P153 An integrated analysis of zoledronic acid (ZA) for prevention of aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

✍ Scribed by A. Brufsky; N. Bundred; R. Coleman; R. Lambert-Falls; R. Mena; M. Dong; N. Schenk; L. Lacerna; E. Perez

Book ID: 114316066
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 46 KB
Volume: 16
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(07)70213-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

P154 Twenty-four month follow-up of the

P154 Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

✍ A. Brufsky; K. Lund; S. Papish; P. Cobb; P. Eisenberg; M. Dong; G. Warsi; L. Lac 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 46 KB

2008 POSTER The E-ZO-FAST trial: Zoledro

2008 POSTER The E-ZO-FAST trial: Zoledronic acid (ZA) effectively inhibits aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (EBC) receiving adjuvant Letrozole (Let)

✍ N. Schenk; A. Lombart; A. Frassoladti; P. Neven; G. Jerusalem; I. Deleu; J. Mebi 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 84 KB

Effective inhibition of aromatase inhibi

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole : ZO-FAST study results

✍ Nigel J. Bundred; Ian D. Campbell; Neville Davidson; Richard H. DeBoer; Holger E 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 158 KB

## Abstract ## BACKGROUND. Letrozole is safe and effective in postmenopausal women with estrogen receptor‐positive early breast cancer, but long‐term aromatase inhibitor use may cause bone loss and increase fracture risk. This study evaluated an immediate or delayed strategy of bone protection the

Zoledronic Acid Effectively Prevents Aro

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

✍ Adam M. Brufsky; Linda D. Bosserman; Richard R. Caradonna; Barbara B. Haley; C. 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 151 KB

P105 Zoledronic acid in the prevention o

P105 Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer

✍ N. Davidson; P. Neven; A. Llombart; N. Bundred; A. Monnier; R. DeBoer; G. Giardi 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 143 KB

Zoledronic acid (ZA) prevents aromatase

Zoledronic acid (ZA) prevents aromatase inhibitor (Al)-associated bone loss in postmenopausal women with early breast cancer -36-month follow-up of the Z-FAST study

✍ A. Brufskv; L. Bosserman; R. Caradonna; B. Haley; M. Jones; H. Moore; M. Dong; G 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 61 KB